NOME E COGNOME
Anastasia De Luca
POSIZIONE
Assistant Professor in Clinical Biochemistry
LUYOGO E DATA DI NASCITA
Rome, August 24th 1982
EDUCAZIONE
INSTITUTO
GRADO
MM/AA
Università di Roma Tor Vergata
Laurea Triennale
07/2004
Biotecnologie
Università di Roma Tor Vergata
Università di Roma Tor Vergata
Laurea Magistrale
PhD
09/2006
11/2009
Biotecnologie Mediche
Biologia Cellulare e Molecolare
Ecole Polytechnique Federale de Lausanne
Borsa di Studio
4-7/2009
biochimica
Universit of Rome “Tor Vergata
Scuola di specializzazion
07/2018
Biochimica Clinica
POSIZIOONI LAVORATIVE
LUOGO ED ISTITUTO
POSIZIONE
MM/AA
PROGETTO
Istituto Dermopatico dell’Immacolata IRCSS, Roma
Post-Doc
11/2009-12/2010
European Project contract
“Novel testing stratrgies for in vitro assesment of allergens”
Università di Roma Tor Vergata
Department odi Scienze e Tecnologie Chimiche
Post-Doc
01/2011-12/2011
“Analysis of the interaction between GST P1-1 and proteins that mediate the apoptotic response of tumors to cytotoxic stimuli”
Università di Roma Tor Vergata
NAST Centre for Nanoscience & Nanotechnology & Innovative Instrumentation
Post-Doc
04/2012-03/2014
“Analysis of the interaction between GST P1-1 and proteins involved in the apoptotic response”
Università di Roma Tor Vergata
NAST Centre for Nanoscience & Nanotechnology & Innovative Instrumentation
Post-Doc
04/2014-04/2015
“Analysis of the therapeutic efficacy of new nitrobenzoxadiazoles on human melanoma models”
Università di Roma Tor Vergata
Department of Experimental Medicine and Surgery
borsa di ricerca della Fondazione Umberto Veronesi
05/2015-04/2016
“Investigation of the effect of novel nitrobenzoxadiazole derivatives on metastatic melanoma”
ISTITUTO E LUOGO
POSIZIONE
MM/YY
PROGETTO
Università di Roma Tor Vergata
Dipartimento di Biomedicina e Prevenzione
Post-Doc
06/2016-12/2016
“Epigenetic and synaptic mechanisms underlying Fragile X syndrome”
Università di Roma Tor Vergata
Dipartimento di Biomedicina e Prevenzione
borsa di ricerca della Fondazione Umberto Veronesi
01/2017-06/2018
“Role of FMRP in circulating breast cancer cells”
University of Rome Tor Vergata
Dipartimento di Biologia
Post-Doc
12/2018-03/2021
“Copper homeostasis in cancer onset and progression”
University of Rome Tor Vergata
Dipartimento di Biologia
borsa d ricerca della Fondazione Umberto Veronesi
04/2021-11/2021
“Dissecting the copper-associated protein network and the effect of extra virgin olive oil derivates during triple negative breast cancer dissemination”
University of Rome Tor Vergata
Dipartimento di Biologia
RTDB biochimica clinica
12/2021-today
Personal Interest
After the master thesis, Dr. De Luca main interests focused on the role of the cell detoxifying system in the acquisition of drug resistance, with particular attention the role of enzyme Glutathione S-transferase P1-1 (GSTP1-1). She studied the efficacy and the biochemical characterization of new ruthenium-based GSTP1-1 inhibitors, developed in collaboration with the Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne where she spent several months. During her stay in Lausanne, under the guidance of Prof. Paul Dyson, she improved the use of techniques such as MALDI-TOF and ESI-MS mass spectrometry as well as being able to take advantage of an international research environment that she has exploited for the construction of new collaborations.
Once back in Rome, she focused her attention on the research of new molecules able to circumvent the acquisition of drug resistance in treating tumors. She contributed significantly to the development of new 6-(7-nitro-2,1,3 benzoxadiazol-4-iltio) hexanol (NBDHEX) derivatives, GSTP1-1 suicide inhibitors, fully characterizing their mechanism of action on a wide panel of different tumor types with the aid of numerous cell biology techniques applied both on human cancer cell cultures and on three-dimensional models of human tumors and mouse xenografts. During this period she acquired a high level of competence in the study of the Mitogen Activated Protein Kinase (MAPK) mediated cell signaling in cancer and in the study, both in vitro and directly within the cell, of protein-protein interactions, creating further collaborations that led her to further expand her skills. The results obtained from this research resulted in several papers published in peer review journals and also in one Italian patent. Of note, her outcomes allowed her to win three times the Fellowship granted from Fondazione Umberto Veronesi.
In December 2021, she obtained the Assistant Professor position, in clinical biochemistry, at the Department of Biology of the University of Rome “Tor Vergata”. She focused her research on the mechanisms underlying cancer dissemination, the epithelial to mesenchymal transition (EMT). Her main interested is on the interconnection between copper homeostasis and EMT in different type of cancers including breast, melanoma, colorectal and pancreatic cancer.
CONGRESS PARTECIPATION
- maggio 29-31, 2023: 7th CANCER WORLD CONGRESS: Palermo (Italy). Invited speaker “Modulation of Copper Homeostasis to Counteract Breast Cancer Dissemination”
- settembre 18-23, 2022 International copper meeting, Sorrento (Italy). Invited speaker “AKT-driven epithelial-mesenchymal transition in triple negative breast cancer is affected by copper bioavailability via a Her2/LOXL2- independent pathway”
- giugno 20-23, 2015 EACR AACR SIC “FROM CANCER BIOLOGY TO THE CLINIC”
Poster Presentation:
• Anastasia De Luca, Graziani G, Rotili D, Muzi A, Mai A, Leonetti C, Artuso S, Bonanno E, Tentori L, Caccuri AM.“A new water-soluble nitrobenzoxadiaxole is highly effective against emurafenib resistant human melanoma cell line”
• Anastasia De Luca, Rotili D, Carpanese D, Mai A, Rosato A, Graziani G, Leonetti C, Geroni C, Quintieri L, Caccuri AM.“Nitrobenzoxadiazoles exert anti-melanoma activity modulating the MAPK/JNK signalling”
- ottobre 14-18, 2012: BIOCHEMISTRY, BIOLOGY AND PATHOLOGY OF MAP KINASES
Poster Presentation:
De Luca Anastasia, Federici L, De Canio M, Stella L, Caccuri AM “New Insights into the Mechanism of JNK1 Inhibition by Glutathione Transferase P1-1”
- giugno 25-30, 2011: 36TH FEBS CONGRESS. BIOCHEMISTRY FOR TOMORROW'S MEDICINE
Poster Presentation:
A. Primavera, Anastasia De Luca, N. Moroni, A. Serafino, R. Petruzzelli, P. S. Vallebona and M. Lo Bello “Treatment of doxorubicin resistant MCF7/dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance”
PUBBLICAZIONI
Italian Patent approved November, 20 2014 N°.1412189
Inventors: Antonello Mai, Anna Maria Caccuri, Luca Federici, Dante Rotili, Anastasia De Luca.
“Derivati del 7-Nitro-2,1,3-Benzossadiazolo per terapia antitumorale”
1. Rapanotti MC, Cugini E, Campione E, Di Raimondo C, Costanza G, Rossi P, Ferlosio A, Bernardini S, Orlandi A, Anastasia De Luca and Bianchi L. Epithelial-to-Mesenchymal Transition Gene Signature in Circulating Melanoma Cells: Biological and Clinical Relevance. Int J Mol Sci. 2023 Jul 22;24(14):11792.
2. Cencelli G, Pacini L, Anastasia De Luca , Messia I, Gentile A, Kang Y, Nobile V, Tabolacci E, Jin P, Farace MG, Bagni C. Age-Dependent Dysregulation of APP in Neuronal and Skin Cells from Fragile X Individuals. Cells. 2023 Feb 27;12(5):758.
3. Turchi R, Tortolici F, Benvenuto M, Punziano C, Anastasia De Luca, Rufini S, Faraonio R, Bei R, Lettieri-Barbato D, Aquilano K. Low Sulfur Amino Acid, High Polyunsaturated Fatty Acid Diet Inhibits Breast Cancer Growth. Int J Mol Sci. 2022 Dec 23;24(1):249.
4. Vitaliti A, Roccatani I, Iorio E, Perta N, Gismondi A, Chirico M, Pisanu ME, Di Marino D, Canini A, Anastasia De Luca A and Rossi L. AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism. Cell Oncol (Dordr). 2023 Feb;46(1):93-115.
5. Vitaliti A, De Luca A, Rossi L. Copper-Dependent Kinases and Their Role in Cancer Inception, Progression and Metastasis. Biomolecules. 2022 Oct 20;12(10):1520.
6. da Silva DA, Anastasia De Luca, Squitti R, Rongioletti M, Rossi L, Machado CML, Cerchiaro G. J. Copper in tumors and the use of copper-based compounds in cancer treatment . Inorg Biochem. 2022 Jan;226:111634.
7. Anastasia De Luca, Fostinelli S, Ferrari C, Binetti G, Benussi L, Borroni B, Rossi L, Rongioletti M, Ghidoni R, Squitti R. Iron Serum Markers Profile in Frontotemporal Lobar Degeneration. J Alzheimers Dis. 2020;78(4):1373-1380.
8. Di Paolo V, Fulci C, Rotili D, Anastasia De Luca, Tomassi S, Serra M, Scimeca M, Geroni C, Quintieri L, Caccuri AM. Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment. Biochem Pharmacol. 2020 Aug;178:114060.
9. Anastasia De Luca, Barile A, Arciello M, Rossi L. Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy . J Trace Elem Med Biol. 2019 Sep;55:204-213.
10. Anastasia De Luca, Parker LJ, Ang WH, Rodolfo C, Gabbarini V, Hancock NC, Palone F, Mazzetti AP, Menin L, Morton CJ, Parker MW, Lo Bello M, Dyson PJ. A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1 . Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):13943-13951.
11. Anastasia De Luca, A. Barile, M. Arciello, L. Rossi. Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy. J TRACE ELEM MED BIO, in press.
12. V. Di Paolo, C. Fulci, D. Rotili, F. Sciarretta, A. Lucidi, B. Morozzo della Rocca, Anastasia De Luca, A. Rosato, L. Quintieri & A.M. Caccuri. Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis.
13. Zalfa F, Panasiti V, Carotti S, Zingariello M, Perrone G, Sancillo L, Pacini L, Luciani F, Roberti V, D'Amico S, Coppola R, Abate SO, Rana RA, De Luca Anastasia, Fiers M, Melocchi V, Bianchi F, Farace MG, Achsel T, Marine JC, Morini S, Bagni C. The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells. Cell Death Dis. 2017 Nov 16;8(11):e3169.
14. Ceccarelli A, Di Venere A, Nicolai E, De Luca Anastasia, Rosato N, Gratton E, Mei G, Caccuri AM. New insight into the interaction of TRAF2 C-terminal domain with lipid raft microdomains. Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):813-822
15. De Luca Anastasia, Carpanese D, Rapanotti MC, Viguria TM, Forgione MA, Rotili D, Fulci C, Iorio E, Quintieri L, Chimenti S, Bianchi L, Rosato A, Caccuri AM. The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis. Oncotarget. 2017 Feb 28;8(9):15520-15538.
16. Fulci C, Rotili D, De Luca Anastasia, Stella L, Morozzo Della Rocca B, Forgione M, Di Paolo V, Mai A, Falconi M, Quintieri L, Caccuri AM. A new nitrobenzoxadiazole-based GSTP1-1 inhibitor with a previously unheard of mechanism of action and high stability. J Enzyme Inhib Med Chem. 2017 Dec;32(1):240-247.
17. Palumbo C, De Luca Anastasia, Rosato N, Forgione M, Rotili D, Caccuri AM. c-Jun Nterminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition. J Transl Med. 2016 Feb 4;14(1):37.
18. Ceccarelli A, Di Venere A, Nicolai E, De Luca Anastasia, Minicozzi V, Rosato N, Caccuri AM, Mei G. TNFR-Associated Factor-2 (TRAF2): Not Only a Trimer. Biochemistry. 2015 Oct 13;54(40):6153-61.
19. Luisi G, Mollica A, Carradori S, Lenoci A, De Luca Anastasia, Caccuri AM. Nitrobenzoxadiazole-based GSTP1-1 inhibitors containing the full peptidyl moiety of (pseudo)glutathione. J Enzyme Inhib Med Chem. 2015 Sep 2:1-7.
20. Graziani G, Artuso S, De Luca Anastasia, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochem Pharmacol. 2015 May 1;95(1):16-27.
21. De Luca Anastasia, Rotili D, Carpanese D, Lenoci A, Calderan L, Scimeca M, Mai A, Bonanno E, Rosato A, Geroni C, Quintieri L, Caccuri AM. A novel orally active watersoluble Inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. Oncotarget. 2015 Feb 28;6(6):4126-43.
22. Rotili D, De Luca Anastasia, Tarantino D, Pezzola S, Forgione M, Morozzo della Rocca B, Falconi M, Mai A, Caccuri AM. Synthesis and Structure-Activity Relationship of New Cytotoxic Agents Targeting Human Glutathione-S-Transferases. Eur J Med Chem. 2015 Jan 7;89:156-71.
23. Avitabile S, Sordi D, Garcovich S, Colonna L, De Luca Anastasia, Nasorri F, Mazzanti C, Cavani A. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patients. J Dermatol. 2014 Dec 12.
24. De Luca Anastasia, Mei G, Rosato N, Nicolai E, Federici L, C Palumbo, Pastore A, Serra M, Caccuri AM. The fine tuning of TRAF2-GSTP1-1 interaction. Effect of ligand binding and in situ detection of the complex. Cell Death Dis. 2014 Jan 23;5:e1015.
25. De Luca Anastasia, Tregno FP, Sau A, Pastore A, Palumbo C, Cicconi R, Federici G, Caccuri AM. Glutathione S-transferase P1-1 as a target for Mesothelioma treatment. Cancer Sci. 2013 Feb;104(2):223-30.
26. Anastasia De Luca, Christian G. Hartinger, Paul J. Dyson, Mario Lo Bello, Angela Casini. A new target for gold(I) compounds: Glutathione-S-transferase inhibition by auranofin. Journal of Inorganic Biochemistry. 2013 Feb;119:38-42. Epub 2012 Aug 24.
27. De Luca Anastasia, Federici L, De Canio M, Stella L, Caccuri AM. New Insights into the Mechanism of JNK1 Inhibition by Glutathione Transferase P1-1.Biochemistry. 2012 Sep 18;51(37):7304-12.
28. Parker LJ, Italiano LC, Morton CJ, Hancock NC, Ascher DB, Aitken JB, Harris HH, Campomanes P, Rothlisberger U, De Luca Anastasia, Lo Bello M, Ang WH, Dyson PJ, Parker MW. Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation. Chemistry. 2011 Jul 4;17(28):7806-16.
29. De Luca Anastasia, Moroni N, Serafino A, Primavera A, Pastore A, Pedersen JZ, Petruzzelli R, Farrace MG, Pierimarchi P, Moroni G, Federici G, Sinibaldi Vallebona P, Lo Bello M. Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochem J. 2011 Dec 1;440(2):175-83.
30. Cavani A, De Luca Anastasia. (2010) Allergic contact dermatitis: novel mechanisms and therapeutic perspectives. Curr Drug Metab. 2010 Mar;11(3):228-33.
31. Fabrini R*, De Luca Anastasia*, Stella L, Mei G, Orioni B, Ciccone S, Federici G, Lo Bello M, Ricci G. Monomer-dimer equilibrium in glutathione transferases: a critical reexamination. Biochemistry. 2009 Nov 3;48(43):10473-82. *equally contributing authors.
32. Ang WH, Parker LJ, De Luca Anastasia, Juillerat-Jeanneret L, Morton CJ, Lo Bello M, Parker MW, Dyson PJ. Rational design of an Organometallic Glutathione Transferase Inhibitor. Angewandte Chemie Int Ed Engl. 2009 Apr 25;48(21):3854-3857.
33. Ang WH; De Luca Anastasia; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ (2007). Organometallic Ruthenium Inhibitors of Glutathione-S-Transferase P1-1 as Anticancer Drugs. CHEMMEDCHEM, vol. 2(12); p. 1799-1806.
NAME
Anastasia De Luca
POSITION TITLE
Assistant Professor in Clinical Biochemistry
PLACE AND DATE OF BIRTH
Rome, August 24th 1982
Education/training
INSTITUTION AND LOCATION
DEGREE
MM/YY
FIELD OF STUDY
University of Rome Tor Vergata
Bachelor
07/2004
Biotechnology
University of Rome Tor Vergata
University of Rome Tor Vergata
Master
PhD
09/2006
11/2009
Medical Biotechnology
Cellular and Molecular Biology
Ecole Polytechnique Federale de Lausanne
Fellowship
4-7/2009
ESI-MS analysis of protein
University of Rome “Tor Vergata
Residency training
07/2018
Clinical Biochemistry
Positions
INSTITUTION AND LOCATION
POSITION
MM/YY
FIELD OF STUDY
Istituto Dermopatico dell’Immacolata IRCSS, Rome
Post-Doc
11/2009-12/2010
European Project contract
“Novel testing stratrgies for in vitro assesment of allergens”
University of Rome Tor Vergata
Department of Chemical Sciences and Technologies
Post-Doc
01/2011-12/2011
“Analysis of the interaction between GST P1-1 and proteins that mediate the apoptotic response of tumors to cytotoxic stimuli”
University of Rome Tor Vergata
NAST Centre for Nanoscience & Nanotechnology & Innovative Instrumentation
Post-Doc
04/2012-03/2014
“Analysis of the interaction between GST P1-1 and proteins involved in the apoptotic response”
University of Rome Tor Vergata
NAST Centre for Nanoscience & Nanotechnology & Innovative Instrumentation
Post-Doc
04/2014-04/2015
“Analysis of the therapeutic efficacy of new nitrobenzoxadiazoles on human melanoma models”
University of Rome Tor Vergata
Department of Experimental Medicine and Surgery
Fellow of Fondazione Umberto Veronesi
05/2015-04/2016
“Investigation of the effect of novel nitrobenzoxadiazole derivatives on metastatic melanoma”
INSTITUTION AND LOCATION
POSITION
MM/YY
FIELD OF STUDY
University of Rome Tor Vergata
Department of Biomedicine and
Prevention
Post-Doc
06/2016-12/2016
“Epigenetic and synaptic mechanisms underlying Fragile X syndrome”
University of Rome Tor Vergata
Department of Biomedicine and
Prevention
Fellow of Fondazione Umberto Veronesi
01/2017-06/2018
“Role of FMRP in circulating breast cancer cells”
University of Rome Tor Vergata
Department of Biology
Post-Doc
12/2018-03/2021
“Copper homeostasis in cancer onset and progression”
University of Rome Tor Vergata
Department of Biology
Fellow of Fondazione Umberto Veronesi
04/2021-11/2021
“Dissecting the copper-associated protein network and the effect of extra virgin olive oil derivates during triple negative breast cancer dissemination”
University of Rome Tor Vergata
Department of Biology
Assistant Professor in Clinical Biochemistry
12/2021-today
“Copper homeostasis in cancer onset and progression”
Personal Interest
After the master thesis, Dr. De Luca main interests focused on the role of the cell detoxifying system in the acquisition of drug resistance, with particular attention the role of enzyme Glutathione S-transferase P1-1 (GSTP1-1). She studied the efficacy and the biochemical characterization of new ruthenium-based GSTP1-1 inhibitors, developed in collaboration with the Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne where she spent several months. During her stay in Lausanne, under the guidance of Prof. Paul Dyson, she improved the use of techniques such as MALDI-TOF and ESI-MS mass spectrometry as well as being able to take advantage of an international research environment that she has exploited for the construction of new collaborations.
Once back in Rome, she focused her attention on the research of new molecules able to circumvent the acquisition of drug resistance in treating tumors. She contributed significantly to the development of new 6-(7-nitro-2,1,3 benzoxadiazol-4-iltio) hexanol (NBDHEX) derivatives, GSTP1-1 suicide inhibitors, fully characterizing their mechanism of action on a wide panel of different tumor types with the aid of numerous cell biology techniques applied both on human cancer cell cultures and on three-dimensional models of human tumors and mouse xenografts. During this period she acquired a high level of competence in the study of the Mitogen Activated Protein Kinase (MAPK) mediated cell signaling in cancer and in the study, both in vitro and directly within the cell, of protein-protein interactions, creating further collaborations that led her to further expand her skills. The results obtained from this research resulted in several papers published in peer review journals and also in one Italian patent. Of note, her outcomes allowed her to win three times the Fellowship granted from Fondazione Umberto Veronesi.
In December 2021, she obtained the Assistant Professor position, in clinical biochemistry, at the Department of Biology of the University of Rome “Tor Vergata”. She focused her research on the mechanisms underlying cancer dissemination, the epithelial to mesenchymal transition (EMT). Her main interested is on the interconnection between copper homeostasis and EMT in different type of cancers including breast, melanoma, colorectal and pancreatic cancer.
Honors
o July 2007: Awarded from the "Rita and Sebastiano Raeli Foundation " for the Best Graduates.
o June 2015: Special Conference EACR AACR SIC “From Cancer Biology to the Clinic”, 20-23 June 2015, Florence
o Travel Grant and “Piero Trivella” Prize to best poster
o March 2018: Awarded for the Best Talk during the “Day of young investigators” March 8, 2018 University of Rome “Tor Vergata”.
Congress Partecipation
- MAY 29-31, 2023: 7th CANCER WORLD CONGRESS: Palermo (Italy)
Invited speaker “Modulation of Copper Homeostasis to Counteract Breast Cancer Dissemination”
- SEPTEMBER 18-23, 2022 International copper meeting, Sorrento (Italy)
Invited speaker “AKT-driven epithelial-mesenchymal transition in triple negative breast cancer is affected by copper bioavailability via a Her2/LOXL2- independent pathway”
- JUNE 20-23, 2015 EACR AACR SIC “FROM CANCER BIOLOGY TO THE CLINIC”
Poster Presentation:
• Anastasia De Luca, Graziani G, Rotili D, Muzi A, Mai A, Leonetti C, Artuso S, Bonanno E, Tentori L, Caccuri AM.“A new water-soluble nitrobenzoxadiaxole is highly effective against emurafenib resistant human melanoma cell line”
• Anastasia De Luca, Rotili D, Carpanese D, Mai A, Rosato A, Graziani G, Leonetti C, Geroni C, Quintieri L, Caccuri AM.“Nitrobenzoxadiazoles exert anti-melanoma activity modulating the MAPK/JNK signalling”
- OCTOBER 14-18, 2012: BIOCHEMISTRY, BIOLOGY AND PATHOLOGY OF MAP KINASES
Poster Presentation:
De Luca Anastasia, Federici L, De Canio M, Stella L, Caccuri AM “New Insights into the Mechanism of JNK1 Inhibition by Glutathione Transferase P1-1”
- UNE 25-30, 2011: 36TH FEBS CONGRESS. BIOCHEMISTRY FOR TOMORROW'S MEDICINE
Poster Presentation:
A. Primavera, Anastasia De Luca, N. Moroni, A. Serafino, R. Petruzzelli, P. S. Vallebona and M. Lo Bello “Treatment of doxorubicin resistant MCF7/dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance”
Peer-reviewed Publications
Italian Patent approved November, 20 2014 N°.1412189
Inventors: Antonello Mai, Anna Maria Caccuri, Luca Federici, Dante Rotili, Anastasia De Luca.
“Derivati del 7-Nitro-2,1,3-Benzossadiazolo per terapia antitumorale”
1. Rapanotti MC, Cugini E, Campione E, Di Raimondo C, Costanza G, Rossi P, Ferlosio A, Bernardini S, Orlandi A, Anastasia De Luca and Bianchi L. Epithelial-to-Mesenchymal Transition Gene Signature in Circulating Melanoma Cells: Biological and Clinical Relevance. Int J Mol Sci. 2023 Jul 22;24(14):11792.
2. Cencelli G, Pacini L, Anastasia De Luca , Messia I, Gentile A, Kang Y, Nobile V, Tabolacci E, Jin P, Farace MG, Bagni C. Age-Dependent Dysregulation of APP in Neuronal and Skin Cells from Fragile X Individuals. Cells. 2023 Feb 27;12(5):758.
3. Turchi R, Tortolici F, Benvenuto M, Punziano C, Anastasia De Luca, Rufini S, Faraonio R, Bei R, Lettieri-Barbato D, Aquilano K. Low Sulfur Amino Acid, High Polyunsaturated Fatty Acid Diet Inhibits Breast Cancer Growth. Int J Mol Sci. 2022 Dec 23;24(1):249.
4. Vitaliti A, Roccatani I, Iorio E, Perta N, Gismondi A, Chirico M, Pisanu ME, Di Marino D, Canini A, Anastasia De Luca A and Rossi L. AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism. Cell Oncol (Dordr). 2023 Feb;46(1):93-115.
5. Vitaliti A, De Luca A, Rossi L. Copper-Dependent Kinases and Their Role in Cancer Inception, Progression and Metastasis. Biomolecules. 2022 Oct 20;12(10):1520.
6. da Silva DA, Anastasia De Luca, Squitti R, Rongioletti M, Rossi L, Machado CML, Cerchiaro G. J. Copper in tumors and the use of copper-based compounds in cancer treatment . Inorg Biochem. 2022 Jan;226:111634.
7. Anastasia De Luca, Fostinelli S, Ferrari C, Binetti G, Benussi L, Borroni B, Rossi L, Rongioletti M, Ghidoni R, Squitti R. Iron Serum Markers Profile in Frontotemporal Lobar Degeneration. J Alzheimers Dis. 2020;78(4):1373-1380.
8. Di Paolo V, Fulci C, Rotili D, Anastasia De Luca, Tomassi S, Serra M, Scimeca M, Geroni C, Quintieri L, Caccuri AM. Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment. Biochem Pharmacol. 2020 Aug;178:114060.
9. Anastasia De Luca, Barile A, Arciello M, Rossi L. Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy . J Trace Elem Med Biol. 2019 Sep;55:204-213.
10. Anastasia De Luca, Parker LJ, Ang WH, Rodolfo C, Gabbarini V, Hancock NC, Palone F, Mazzetti AP, Menin L, Morton CJ, Parker MW, Lo Bello M, Dyson PJ. A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1 . Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):13943-13951.
11. Anastasia De Luca, A. Barile, M. Arciello, L. Rossi. Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy. J TRACE ELEM MED BIO, in press.
12. V. Di Paolo, C. Fulci, D. Rotili, F. Sciarretta, A. Lucidi, B. Morozzo della Rocca, Anastasia De Luca, A. Rosato, L. Quintieri & A.M. Caccuri. Synthesis and characterisation of a new benzamide-containing nitrobenzoxadiazole as a GSTP1-1 inhibitor endowed with high stability to metabolic hydrolysis.
13. Zalfa F, Panasiti V, Carotti S, Zingariello M, Perrone G, Sancillo L, Pacini L, Luciani F, Roberti V, D'Amico S, Coppola R, Abate SO, Rana RA, De Luca Anastasia, Fiers M, Melocchi V, Bianchi F, Farace MG, Achsel T, Marine JC, Morini S, Bagni C. The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells. Cell Death Dis. 2017 Nov 16;8(11):e3169.
14. Ceccarelli A, Di Venere A, Nicolai E, De Luca Anastasia, Rosato N, Gratton E, Mei G, Caccuri AM. New insight into the interaction of TRAF2 C-terminal domain with lipid raft microdomains. Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):813-822
15. De Luca Anastasia, Carpanese D, Rapanotti MC, Viguria TM, Forgione MA, Rotili D, Fulci C, Iorio E, Quintieri L, Chimenti S, Bianchi L, Rosato A, Caccuri AM. The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasis. Oncotarget. 2017 Feb 28;8(9):15520-15538.
16. Fulci C, Rotili D, De Luca Anastasia, Stella L, Morozzo Della Rocca B, Forgione M, Di Paolo V, Mai A, Falconi M, Quintieri L, Caccuri AM. A new nitrobenzoxadiazole-based GSTP1-1 inhibitor with a previously unheard of mechanism of action and high stability. J Enzyme Inhib Med Chem. 2017 Dec;32(1):240-247.
17. Palumbo C, De Luca Anastasia, Rosato N, Forgione M, Rotili D, Caccuri AM. c-Jun Nterminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition. J Transl Med. 2016 Feb 4;14(1):37.
18. Ceccarelli A, Di Venere A, Nicolai E, De Luca Anastasia, Minicozzi V, Rosato N, Caccuri AM, Mei G. TNFR-Associated Factor-2 (TRAF2): Not Only a Trimer. Biochemistry. 2015 Oct 13;54(40):6153-61.
19. Luisi G, Mollica A, Carradori S, Lenoci A, De Luca Anastasia, Caccuri AM. Nitrobenzoxadiazole-based GSTP1-1 inhibitors containing the full peptidyl moiety of (pseudo)glutathione. J Enzyme Inhib Med Chem. 2015 Sep 2:1-7.
20. Graziani G, Artuso S, De Luca Anastasia, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochem Pharmacol. 2015 May 1;95(1):16-27.
21. De Luca Anastasia, Rotili D, Carpanese D, Lenoci A, Calderan L, Scimeca M, Mai A, Bonanno E, Rosato A, Geroni C, Quintieri L, Caccuri AM. A novel orally active watersoluble Inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. Oncotarget. 2015 Feb 28;6(6):4126-43.
22. Rotili D, De Luca Anastasia, Tarantino D, Pezzola S, Forgione M, Morozzo della Rocca B, Falconi M, Mai A, Caccuri AM. Synthesis and Structure-Activity Relationship of New Cytotoxic Agents Targeting Human Glutathione-S-Transferases. Eur J Med Chem. 2015 Jan 7;89:156-71.
23. Avitabile S, Sordi D, Garcovich S, Colonna L, De Luca Anastasia, Nasorri F, Mazzanti C, Cavani A. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patients. J Dermatol. 2014 Dec 12.
24. De Luca Anastasia, Mei G, Rosato N, Nicolai E, Federici L, C Palumbo, Pastore A, Serra M, Caccuri AM. The fine tuning of TRAF2-GSTP1-1 interaction. Effect of ligand binding and in situ detection of the complex. Cell Death Dis. 2014 Jan 23;5:e1015.
25. De Luca Anastasia, Tregno FP, Sau A, Pastore A, Palumbo C, Cicconi R, Federici G, Caccuri AM. Glutathione S-transferase P1-1 as a target for Mesothelioma treatment. Cancer Sci. 2013 Feb;104(2):223-30.
26. Anastasia De Luca, Christian G. Hartinger, Paul J. Dyson, Mario Lo Bello, Angela Casini. A new target for gold(I) compounds: Glutathione-S-transferase inhibition by auranofin. Journal of Inorganic Biochemistry. 2013 Feb;119:38-42. Epub 2012 Aug 24.
27. De Luca Anastasia, Federici L, De Canio M, Stella L, Caccuri AM. New Insights into the Mechanism of JNK1 Inhibition by Glutathione Transferase P1-1.Biochemistry. 2012 Sep 18;51(37):7304-12.
28. Parker LJ, Italiano LC, Morton CJ, Hancock NC, Ascher DB, Aitken JB, Harris HH, Campomanes P, Rothlisberger U, De Luca Anastasia, Lo Bello M, Ang WH, Dyson PJ, Parker MW. Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation. Chemistry. 2011 Jul 4;17(28):7806-16.
29. De Luca Anastasia, Moroni N, Serafino A, Primavera A, Pastore A, Pedersen JZ, Petruzzelli R, Farrace MG, Pierimarchi P, Moroni G, Federici G, Sinibaldi Vallebona P, Lo Bello M. Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochem J. 2011 Dec 1;440(2):175-83.
30. Cavani A, De Luca Anastasia. (2010) Allergic contact dermatitis: novel mechanisms and therapeutic perspectives. Curr Drug Metab. 2010 Mar;11(3):228-33.
31. Fabrini R*, De Luca Anastasia*, Stella L, Mei G, Orioni B, Ciccone S, Federici G, Lo Bello M, Ricci G. Monomer-dimer equilibrium in glutathione transferases: a critical reexamination. Biochemistry. 2009 Nov 3;48(43):10473-82. *equally contributing authors.
32. Ang WH, Parker LJ, De Luca Anastasia, Juillerat-Jeanneret L, Morton CJ, Lo Bello M, Parker MW, Dyson PJ. Rational design of an Organometallic Glutathione Transferase Inhibitor. Angewandte Chemie Int Ed Engl. 2009 Apr 25;48(21):3854-3857.
33. Ang WH; De Luca Anastasia; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ (2007). Organometallic Ruthenium Inhibitors of Glutathione-S-Transferase P1-1 as Anticancer Drugs. CHEMMEDCHEM, vol. 2(12); p. 1799-1806.